Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis

Author： Palacios Santiago

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.26, Iss.7, 2010-07, pp. : 1553-1563

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis – a clinical update on efficacy and safety

By Deal Chad L Draper Michael W

Women's Health, Vol. 2, Iss. 2, 2006-03 ,pp. : 199-210

Future Medicine

Access to resources Recommend Favorite

Bazedoxifene: a selective estrogen-receptor modulator

By Mitwally Mohamed FM

Women's Health, Vol. 4, Iss. 4, 2008-07 ,pp. : 319-326

Future Medicine

Access to resources Recommend Favorite

Efficacy and safety of bazedoxifene in postmenopausal Asian women

By Xu L. Tsai K.-S. Kim G. Wu Y. Vincendon P. Chines A. Constantine G.

Osteoporosis International, Vol. 22, Iss. 2, 2011-02 ,pp. : 559-565

Springer Publishing Company

Access to resources Recommend Favorite

Raloxifene: a selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women

By Vogel Victor G

Women's Health, Vol. 3, Iss. 2, 2007-03 ,pp. : 139-153

Future Medicine

Access to resources Recommend Favorite

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis

By Iwamoto Jun Takeda Tsuyoshi Sato Yoshihiro

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 919-928

Informa Healthcare

Access to resources Recommend Favorite